Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Front Chem ; 9: 803464, 2021.
Article in English | MEDLINE | ID: mdl-34957055

ABSTRACT

Co3O4 is an environmental catalyst that can effectively decompose ozone, but is strongly affected by water vapor. In this study, Co3O4@SiO2 catalysts with a core-shell-like structure were synthesized following the hydrothermal method. At 60% relative humidity and a space velocity of 720,000 h-1, the prepared Co3O4@SiO2 obtained 95% ozone decomposition for 40 ppm ozone after 6 h, which far outperformed that of the 25wt% Co3O4/SiO2 catalysts. The superiority of Co3O4@SiO2 is ascribed to its core@shell structure, in which Co3O4 is wrapped inside the SiO2 shell structure to avoid air exposure. This research provides important guidance for the high humidity resistance of catalysts for ozone decomposition.

2.
Cancer Manag Res ; 13: 1-11, 2021.
Article in English | MEDLINE | ID: mdl-33442289

ABSTRACT

BACKGROUND: Circ_0004771 was demonstrated to mediate cell growth promotion and apoptosis suppression in breast cancer (BC). Herein, the precise functions and mechanism of circ_0004771 in the biological property of BC cells were investigated. METHODS: The expression of circ_0004771, microRNA (miR)-1253 and dimethylarginine dimethylaminohydrolase 1 (DDAH1) mRNA was analyzed using quantitative real-time polymerase chain reaction. The proliferation, apoptosis, migration, invasion, adhesion, Western blot and in vivo tumorigenesis assays were employed to evaluate the roles of circ_0004771 and DDAH1 in BC tumorigenesis. The interaction between miR-1253 and circ_0004771 or DDAH1 was validated by dual-luciferase reporter, pull-down and RNA immunoprecipitation (RIP) assay. Exosomes were isolated by Exoquick-TC® methods, and qualified using Nanosight™ technology and Western blot. RESULTS: Circ_0004771 or DDAH1 expression was elevated in BC, and silencing either of them suppressed cell malignant phenotypes, thus impeding BC progression. Importantly, circ_0004771 up-regulation attenuated the anticancer action of DDAH1-knockdown in BC. Additionally, we confirmed that circ_0004771 functioned as a sponge of miR-1253 to up-regulate DDAH1 expression. Moreover, xenograft assay exhibited that circ_0004771 knockdown also hindered tumor growth in vivo via regulating DDAH1 and miR-1253. Besides that, it was found that circ_0004771 was packaged into exosomes isolated from the serum of BC. CONCLUSION: Circ_0004771 accelerated cell carcinogenic phenotypes via up-regulating DDAH1 expression through absorbing miR-1253 in BC. Besides, circ_0004771 was packaged into exosomes isolated from the serum of BC. All these findings suggested a promising molecular target for BC treatment.

3.
Biosci Biotechnol Biochem ; 84(12): 2415-2424, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32942951

ABSTRACT

This study aims to discover the effects of ursolic acid (UA) on papillary thyroid carcinoma (PTC). Human PTC cells were under UA treatment, and cell viability, clone formation, and apoptosis were measured by MTT assay, clone formation assay, and flow cytometry, respectively. Expressions of apoptosis- and epithelial-mesenchymal transition (EMT)-related markers were determined via qRT-PCR and western blot. Fibronectin-1 (FN1) expression in thyroid carcinoma was analyzed by GEPIA2 and qRT-PCR. The effects of overexpressed FN1 on UA-treated cells were detected following the previous procedures. Cell viability, proliferation, and EMT-related marker expressions were inhibited, while cell apoptosis and apoptosis-related marker expressions were promoted by UA. FN1 was higher expressed in thyroid carcinoma and downregulated by UA. Effects of FN1 on cell viability, proliferation, and apoptosis- and EMT-related marker expressions were partially reversed by UA. UA inhibited human PTC cell viability, proliferation, and EMT but promoted apoptosis via suppressing FN1.


Subject(s)
Antineoplastic Agents/pharmacology , Fibronectins/antagonists & inhibitors , Thyroid Cancer, Papillary/pathology , Triterpenes/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Epithelial-Mesenchymal Transition/drug effects , Fibronectins/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Humans , Ursolic Acid
4.
Pharm Res ; 36(8): 121, 2019 Jun 18.
Article in English | MEDLINE | ID: mdl-31214786

ABSTRACT

PURPOSE: ß-elemene and cisplatin combined chemotherapy currently is one of the most important settings available for lung cancer therapy in China. However, the clinical outcome is limited by their pharmacokinetic drawbacks. On the other hand, most of nanomedicines have failed in clinical development due to the huge differences between heterogeneous clinical tumor tissues and homogenous cell-derived xenografts. In this work, we fabricated a ß-elemene and cisplatin co-loaded liposomal system to effectively treat lung cancer. METHOD: In vitro cytotoxicity of co-loaded liposomes was studied by MTT, trypan and Hoechst/PI staining, and western blot in A549, A549/DDP, and LCC cells. In vivo antitumor efficacy was evaluated in cell-derived and clinically relevant patient-derived xenografts. RESULTS: Co-loaded liposomes were more cytotoxic to cancer cells, especially than the combination of single-loaded liposomes, benefiting from their simultaneous drug internalization and release. As a result, they exhibited desirable therapeutic outcome in both cell-derived and patient-derived xenografts. CONCLUSION: ß-elemene and cisplatin co-loaded liposomes are a clinically promising candidate for effective lung cancer therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Cisplatin/pharmacokinetics , Liposomes/chemistry , Lung Neoplasms/drug therapy , Sesquiterpenes/pharmacokinetics , A549 Cells , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cell Survival/drug effects , Cholesterol/chemistry , Cisplatin/administration & dosage , Drug Compounding , Drug Liberation , Heterografts , Humans , Mice, Inbred C57BL , Particle Size , Phosphatidylcholines/chemistry , Phosphatidylethanolamines/chemistry , Polyethylene Glycols/chemistry , Sesquiterpenes/administration & dosage , Tissue Distribution
5.
Colloids Surf B Biointerfaces ; 172: 37-42, 2018 Dec 01.
Article in English | MEDLINE | ID: mdl-30130635

ABSTRACT

The purpose of this study was to fabricate a novel binary hydrogel, and the insulin-loaded hydrogel was used as rectal suppository to prevent type I diabetes. The binary hydrogel was synthesized via solution polymerization. Its structure was studied by Fourier transform infrared spectroscopy (FTIR) and Raman spectra. The swelling behaviors of binary hydrogels were revealed in pH 1.2, 6.8 and 7.4 buffers, respectively. Their inner morphologies were observed with a scanning electron microscope (SEM). Insulin (INS) was selected as a model drug and encapsulated into the binary hydrogels. INS release study was carried out in pH 7.4 buffer. The hypoglycemic effects of INS-loaded hydrogels were studied by rectal administration. FTIR and Raman spectra confirmed the obtaining of binary hydrogels. The hydrogel showed a high swelling ratio in pH 7.4 (rectum environment). SEM photographs illustrated that many micro-pores in the inner of binary hydrogels, which could accommodate abundant guest molecule (e.g. INS). INS release profile suggested that INS-loaded hydrogels could diffuse INS at a sustained manner. Animal studies proved that INS-loaded binary hydrogel had an obvious hypoglycemic effect. Therefore, it could be speculated that the binary hydrogel had a potential application on treating type I diabetes by rectal administration.


Subject(s)
Acrylic Resins/chemistry , Diabetes Mellitus, Type 1/prevention & control , Hydrogels/chemistry , Methylcellulose/chemistry , Rectum/physiology , Animals , Blood Glucose/metabolism , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/prevention & control , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/pathology , Hypoglycemic Agents/therapeutic use , Male , Rats, Sprague-Dawley , Spectroscopy, Fourier Transform Infrared , Spectrum Analysis, Raman , Suppositories , Thermogravimetry , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL